Display options
Cite
Rigolet M, Aouizerate J, Couette M, et al. Clinical features in patients with long-lasting macrophagic myofasciitis. Front Neurol. 2014;5:230doi: 10.3389/fneur.2014.00230.
Rigolet, M., Aouizerate, J., Couette, M., Ragunathan-Thangarajah, N., Aoun-Sebaiti, M., Gherardi, R. K., Cadusseau, J., & Authier, F. J. (2014). Clinical features in patients with long-lasting macrophagic myofasciitis. Frontiers in neurology, 5230. https://doi.org/10.3389/fneur.2014.00230
Rigolet, Muriel, et al. "Clinical features in patients with long-lasting macrophagic myofasciitis." Frontiers in neurology vol. 5 (2014): 230. doi: https://doi.org/10.3389/fneur.2014.00230
Rigolet M, Aouizerate J, Couette M, Ragunathan-Thangarajah N, Aoun-Sebaiti M, Gherardi RK, Cadusseau J, Authier FJ. Clinical features in patients with long-lasting macrophagic myofasciitis. Front Neurol. 2014 Nov 28;5:230. doi: 10.3389/fneur.2014.00230. eCollection 2014. PMID: 25506338; PMCID: PMC4246686.
Copy Download .nbib Format: NLM
Share it on

Front Neurol. 2014 Nov 28;5:230. doi: 10.3389/fneur.2014.00230. eCollection 2014.

Clinical features in patients with long-lasting macrophagic myofasciitis.

Frontiers in neurology

Muriel Rigolet, Jessie Aouizerate, Maryline Couette, Nilusha Ragunathan-Thangarajah, Mehdi Aoun-Sebaiti, Romain Kroum Gherardi, Josette Cadusseau, François Jérôme Authier

Affiliations

  1. Faculty of Medicine, INSERM U955-Team 10 , Créteil , France.
  2. Faculty of Medicine, INSERM U955-Team 10 , Créteil , France ; Reference Center for Neuromuscular Diseases Garches-Necker-Mondor-Hendaye , Créteil , France.
  3. Neurology Department, Henri Mondor University Hospital , Créteil , France.
  4. Faculty of Medicine, INSERM U955-Team 10 , Créteil , France ; Reference Center for Neuromuscular Diseases Garches-Necker-Mondor-Hendaye , Créteil , France ; Paris Est-Créteil University , Créteil , France.
  5. Reference Center for Neuromuscular Diseases Garches-Necker-Mondor-Hendaye , Créteil , France ; Paris Est-Créteil University , Créteil , France.

PMID: 25506338 PMCID: PMC4246686 DOI: 10.3389/fneur.2014.00230

Abstract

Macrophagic myofasciitis (MMF) is an emerging condition characterized by specific muscle lesions assessing abnormal long-term persistence of aluminum hydroxide within macrophages at the site of previous immunization. Affected patients usually are middle-aged adults, mainly presenting with diffuse arthromyalgias, chronic fatigue, and marked cognitive deficits, not related to pain, fatigue, or depression. Clinical features usually correspond to that observed in chronic fatigue syndrome/myalgic encephalomyelitis. Representative features of MMF-associated cognitive dysfunction include dysexecutive syndrome, visual memory impairment, and left ear extinction at dichotic listening test. Most patients fulfill criteria for non-amnestic/dysexecutive mild cognitive impairment, even if some cognitive deficits appear unusually severe. Cognitive dysfunction seems stable over time despite marked fluctuations. Evoked potentials may show abnormalities in keeping with central nervous system involvement, with a neurophysiological pattern suggestive of demyelination. Brain perfusion SPECT shows a pattern of diffuse cortical and subcortical abnormalities, with hypoperfusions correlating with cognitive deficiencies. The combination of musculoskeletal pain, chronic fatigue, and cognitive disturbance generates chronic disability with possible social exclusion. Classical therapeutic approaches are usually unsatisfactory making patient care difficult.

Keywords: CCL2; aluminum; chronic fatigue syndrome; mild cognitive impairment; myalgias; myofasciitis; neglected diseases; vaccines

References

  1. BMC Med. 2013 Apr 04;11:99 - PubMed
  2. J Rheumatol. 2004 Nov;31(11):2313-4 - PubMed
  3. Med Hypotheses. 2009 Feb;72(2):135-9 - PubMed
  4. Lupus. 2012 Feb;21(2):184-9 - PubMed
  5. Vaccine. 1997 Aug-Sep;15(12-13):1314-8 - PubMed
  6. Clin Rev Allergy Immunol. 2011 Oct;41(2):163-8 - PubMed
  7. Neuromuscul Disord. 2006 May;16(5):347-52 - PubMed
  8. Am J Med. 1992 Mar;92(3):254-6 - PubMed
  9. Neuromuscul Disord. 2004 Apr;14(4):246-52 - PubMed
  10. Rheumatol Int. 2015 Jan;35(1):189-92 - PubMed
  11. Vaccine. 2005 Feb 3;23(11):1359-67 - PubMed
  12. BMC Biol. 2010 Apr 12;8:37 - PubMed
  13. J Inorg Biochem. 2013 Nov;128:262-6 - PubMed
  14. Annu Rev Med. 1998;49:1-13 - PubMed
  15. J Inorg Biochem. 2011 Nov;105(11):1457-63 - PubMed
  16. Lancet. 1991 Sep 21;338(8769):707-12 - PubMed
  17. Arthritis Rheum. 2002 Sep;46(9):2535-7 - PubMed
  18. Brain. 2001 Sep;124(Pt 9):1821-31 - PubMed
  19. Blood. 1996 Mar 15;87(6):2095-147 - PubMed
  20. Wkly Epidemiol Rec. 1999 Oct 15;74(41):337-40 - PubMed
  21. Arthritis Rheum. 2000 Jul;43(7):1520-6 - PubMed
  22. Neurology. 2007 Jan 16;68(3):170-1 - PubMed
  23. Joint Bone Spine. 2003 Aug;70(4):242-5 - PubMed
  24. Curr Med Chem. 2014;21(4):511-7 - PubMed
  25. Autoimmun Rev. 2008 Oct;8(1):52-5 - PubMed
  26. Arthritis Rheum. 2003 Feb;48(2):569-70 - PubMed
  27. Lancet. 1998 Aug 1;352(9125):347-52 - PubMed
  28. Bull Acad Natl Med. 2003;187(8):1511-8; discussion 1519-21 - PubMed
  29. J Autoimmun. 2011 Feb;36(1):4-8 - PubMed
  30. Brain. 2001 May;124(Pt 5):974-83 - PubMed
  31. Arthritis Rheum. 1990 Feb;33(2):160-72 - PubMed
  32. Neuromuscul Disord. 2001 Jul;11(5):452-7 - PubMed
  33. Arthritis Rheum. 2002 Oct 15;47(5):543-5 - PubMed
  34. J Inorg Biochem. 2009 Nov;103(11):1571-8 - PubMed
  35. Ann Rheum Dis. 2000 Nov;59(11):927-8 - PubMed
  36. Hum Vaccin. 2007 Jul-Aug;3(4):139-45 - PubMed
  37. Presse Med. 2005 Mar 26;34(6):438-40 - PubMed
  38. Immunol Allergy Clin North Am. 2003 Nov;23(4):699-712 - PubMed

Publication Types